

Important: Read Carefully!

Fusibact BTM

fusidic acid, betamethasone valerate

CREAM

COMPOSITION:

Each gram of Fusibact BTM cream contains, fusidic acid 20 mg and betamethasone valerate 1.0 mg in suitable cream base.

PHARMACOLOGY:

Fusidic acid is non-beta lactam potent antibacterial agent, that is both water and fat soluble with the ability to penetrate intact skin. It is active against nearly all strains of Staphylococcus aureus include penicillinase and non-penicillinase producing. The antibacterial action of fusidic acid results from the inhibition of bacterial protein synthesis. The drug interferes with amino acid transfer from amino acetyl sRNA to protein on ribosome. Fusidic acid is active in vitro against gram- positive bacteria and Neisseria species but has almost no antibacterial activity against gram-negative organisms. Betamethasone valerate is a potent topical corticosteroid. The class of compound, used primarily for their anti - inflammatory, anti - pruritic and / or immunosuppressive effect, and vasoconstrictive action. Some systemic absorption of the drug may occur. If the cream is used as per the direction the side effects due to systemic absorption can be avoided. The cream is most suitable for most of the dermatoses. Betamethasone valerate is absorbed through the skin. The proportion of the drug absorbed through the skin depends on the vehicle and the severity of the damage to the stratum corneum barrier caused by the skin disease.

INDICATIONS:

Fusibact BTM is indicated in treatment of inflammatory dermatoses where bacterial infection is present or likely to occur. Inflammatory dermatoses include atopic eczema, discoid eczema, stasis eczema, seborrhoeic dermatitis, contact dermatitis, lichen simplex chronicus, psoriasis, discoid lupus erythematosus.

CONTRAINDICATION:

Known hypersensitivity to components.

PRECAUTIONS:

In prolonged or extensive use, systemic absorption of topical corticosteroids has resulted in reversible HPA axis suppression, manifestation of Cushing's syndrome, hyperglycemia and glucosuria.

Children may absorb larger amounts and be more susceptible to toxicity to the use of corticosteroid. The cream should not be used with occlusive dressing. Caution when using treatment near the eye. Discontinue if irritation or sensitivity occurs.

SIDE EFFECTS:

Skin rashes, mild stinging, and irritation on application has been reported rarely.

DOSAGE AND ADMINISTRATION:

Apply on effected area 2-3 times a day.

STORAGE: Store below 30 °C.

PRESENTATION:

Fusibact BTM cream, 15 gm in aluminium collapsible tube.

THIS IS A MEDICAMENT

- Medicament is a product that affects your health, and its consumption contrary to instructions is dangerous for you.
- Follow strictly the doctor's prescription, the method of use and the instructions of the pharmacist who sold the medicament.
- The doctor and the pharmacist are experts in medicine, its benefits and risks.
- Do not by yourself interrupt the period of treatment prescribed.
- Do not repeat the same prescription without consulting your doctor.

Keep medicament out of reach of children.

Council of Arab Health Ministers & Union of Arab Pharmacists

 Derma

Fusibact BTM is a quality product manufactured by:

 جمجوم فارما
Jamjoom Pharma

P.O.Box 6267 Jeddah - 21442- Saudi Arabia

32171046 - Rev. 03S/17-08-10